284 related articles for article (PubMed ID: 10825037)
1. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.
Derkx B; Wittes J; McCloskey R
Clin Infect Dis; 1999 Apr; 28(4):770-7. PubMed ID: 10825037
[TBL] [Abstract][Full Text] [Related]
2. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
3. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study.
de Kleijn ED; de Groot R; Hack CE; Mulder PG; Engl W; Moritz B; Joosten KF; Hazelzet JA
Crit Care Med; 2003 Jun; 31(6):1839-47. PubMed ID: 12794428
[TBL] [Abstract][Full Text] [Related]
4. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
[TBL] [Abstract][Full Text] [Related]
5. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
[TBL] [Abstract][Full Text] [Related]
7. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Barriere SL; Guglielmo BJ
Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock.
Stephens DP; Thomas JH; Higgins A; Bailey M; Anstey NM; Currie BJ; Cheng AC
Crit Care Med; 2008 Feb; 36(2):448-54. PubMed ID: 18216600
[TBL] [Abstract][Full Text] [Related]
9. Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide.
Bogard WC; Siegel SA; Leone AO; Damiano E; Shealy DJ; Ely TM; Frederick B; Mascelli MA; Siegel RC; Machielse B
J Immunol; 1993 May; 150(10):4438-49. PubMed ID: 7683319
[TBL] [Abstract][Full Text] [Related]
10. Antiendotoxin therapy in sepsis.
Colletti RC; Dew RB; Goulart AE
Crit Care Nurs Clin North Am; 1993 Jun; 5(2):345-54. PubMed ID: 8398040
[TBL] [Abstract][Full Text] [Related]
11. Does granulocyte colony-stimulating factor ameliorate the proinflammatory response in human meningococcal septic shock?
Rojahn A; Brusletto B; Øvstebø R; Haug KB; Kierulf P; Brandtzaeg P
Crit Care Med; 2008 Sep; 36(9):2583-9. PubMed ID: 18679115
[TBL] [Abstract][Full Text] [Related]
12. Meningococcal septic shock: is insulin lifesaving in children?
Mormile R; De Michele M
Int J Infect Dis; 2011 Jul; 15(7):e504. PubMed ID: 21530349
[No Abstract] [Full Text] [Related]
13. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
Watson D; Grover R; Anzueto A; Lorente J; Smithies M; Bellomo R; Guntupalli K; Grossman S; Donaldson J; Le Gall JR;
Crit Care Med; 2004 Jan; 32(1):13-20. PubMed ID: 14707555
[TBL] [Abstract][Full Text] [Related]
14. Early application of generic mortality risk scores in presumed meningococcal disease.
Festa MS; Tibby SM; Taylor D; Durward A; Habibi P; Murdoch IA
Pediatr Crit Care Med; 2005 Jan; 6(1):9-13. PubMed ID: 15636652
[TBL] [Abstract][Full Text] [Related]
15. Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans.
Khazaeli MB; Wheeler R; Rogers K; Teng N; Ziegler E; Haynes A; Saleh MN; Hardin JM; Bolmer S; Cornett J
J Biol Response Mod; 1990 Apr; 9(2):178-84. PubMed ID: 2341860
[TBL] [Abstract][Full Text] [Related]
16. Fluconazole improves survival in septic shock: a randomized double-blind prospective study.
Jacobs S; Price Evans DA; Tariq M; Al Omar NF
Crit Care Med; 2003 Jul; 31(7):1938-46. PubMed ID: 12847386
[TBL] [Abstract][Full Text] [Related]
17. Mortality rates in pediatric septic shock with and without multiple organ system failure.
Kutko MC; Calarco MP; Flaherty MB; Helmrich RF; Ushay HM; Pon S; Greenwald BM
Pediatr Crit Care Med; 2003 Jul; 4(3):333-7. PubMed ID: 12831416
[TBL] [Abstract][Full Text] [Related]
18. The current management of septic shock.
Russel JA
Minerva Med; 2008 Oct; 99(5):431-58. PubMed ID: 18971911
[TBL] [Abstract][Full Text] [Related]
19. Plasma interferon-gamma and interleukin-10 concentrations in systemic meningococcal disease compared with severe systemic Gram-positive septic shock.
Bjerre A; Brusletto B; Høiby EA; Kierulf P; Brandtzaeg P
Crit Care Med; 2004 Feb; 32(2):433-8. PubMed ID: 14758160
[TBL] [Abstract][Full Text] [Related]
20. [Fulminant meningococcemia treated with antiendotoxin IgM monoclonal antibodies (HA-1A)].
Gómez-Jiménez J; Peracaula Picart R; Jódar Masanes R; Montoro Ronsano B
Med Clin (Barc); 1993 Mar; 100(10):394-5. PubMed ID: 8474285
[No Abstract] [Full Text] [Related]
[Next] [New Search]
